Search Results 5991-6000 of 25092 for oral

1. Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1) - Mayo Clinic

   ... oral or parenteral corticosteroids * Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide ...

2. Medical Dermatology Fellowship (Minnesota) - Mayo Clinic College of Medicine and Science

   ... oral disease, vulvar dermatology (in collaboration with gynecology) and contact dermatitis or patch test clinic. You will have the ability to select to be ...

3. Mayo Clinic Q and A: 6 UTI myths and facts

   Urinary tract infections, also called UTIs, are the most common infection for women in the U.S..

4. Nonmelanoma skin cancer - Doctors and departments - Mayo Clinic

   ... Oral and throat cancer, Adenocarcinoma, Tongue base cancer, Oropharyngeal cancer. Show more areas of focus for Eric J. Moore, M.D. ...

5. Safe Omission of Pelvic Lymph Node Dissection During Radical Prostatectomy - Mayo Clinic

   Patients that have had prior hormonal therapy such as Lupron or oral anti-androgens. Clinical oligometastatic disease with > 3 nodes positive on 18F-rhPSMA ...

6. A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer (ASCLEPIuS) - Mayo Clinic

   ... oral ketoconazole, chemotherapy, immunotherapy, estrogens, radiopharmaceuticals. 9. History of prior pelvic radiation therapy 10. Concurrent treatment with ...

7. VE303 for Prevention of Recurrent Clostridioides Difficile Infection - Mayo Clinic

   ... oral or parenteral antibacterial therapy for a non-CDI indication after randomization. Note: Other protocol defined Inclusion/Exclusion Criteria may apply ...

8. Cross-Variant Memory B Cell and T Cell Responses After COVID-19 mRNA Vaccine Booster - Mayo Clinic

   Preventative use of antibiotics (i.e. oral surgery) is not an exclusion criterion. Diagnosis of a cognitive disorder (e.g., Alzheimer's, Dementia). Anemia ...

9. Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck - Mayo Clinic

   Eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx. Participants must not have received prior systemic therapy for R/M ...

10. Throat cancer - Doctors and departments - Mayo Clinic

    Oral and Maxillofacial Surgery · Oropharynx Cancer Clinic in Minnesota · Otolaryngology (ENT)/Head and Neck Surgery · Pediatric Hematology/Oncology · Plastic ...